| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
|
|---|
| Outline of Final Research Achievements |
The number of bone-related disease patients is increasing in Japan. At present, bisphosphonates are widely used for these diseases, but their severe side effects are impossible to ignore.
We focused on TPh A, a Pirin inhibitor, as a novel drug for such diseases. We assayed many derivatives of TPh A and found that 2 compounds inhibited RANKL-induced osteoclastgenesis on Pirin-independent manner without cytotoxicity. These compounds did not suppress phosphorylation of MAPKs, although its inhibited expression of c-Fos and DC-STAMP. Therefore, it is suggested that the compounds we found might be candidates for drugs of bone-related diseases.
|
